Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned an average rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $65.00.

Several research firms have issued reports on ARCT. BTIG Research initiated coverage on Arcturus Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $41.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. nVerses Capital LLC bought a new stake in shares of Arcturus Therapeutics in the 3rd quarter worth approximately $42,000. KLP Kapitalforvaltning AS bought a new stake in Arcturus Therapeutics in the fourth quarter valued at $71,000. National Bank of Canada FI boosted its holdings in shares of Arcturus Therapeutics by 639.6% during the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 4,784 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Arcturus Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 2,038 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Arcturus Therapeutics during the third quarter worth about $191,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Price Performance

ARCT opened at $15.86 on Thursday. The stock has a market capitalization of $429.65 million, a price-to-earnings ratio of -7.14 and a beta of 2.62. Arcturus Therapeutics has a 12 month low of $14.30 and a 12 month high of $45.00. The business has a 50-day moving average of $17.09 and a two-hundred day moving average of $19.06.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.